Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study

医学 腹腔疾病 安慰剂 内科学 临床终点 胃肠病学 人口 不利影响 绒毛萎缩 面筋 临床试验 疾病 病理 环境卫生 替代医学
作者
Marja‐Leena Lähdeaho,Mika Scheinin,Pekka Vuotikka,Juha Taavela,Alina Popp,Johanna Laukkarinen,Jukka Koffert,Olli‐Pekka Koivurova,Marko Pesu,Laura Kivelä,Zsófia Lovró,Joni Keisala,Jorma Isola,Jane R. Parnes,Francisco León,Markku Mäki
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (12): 948-959 被引量:74
标识
DOI:10.1016/s2468-1253(19)30264-x
摘要

Background Interleukin 15 (IL-15) is implicated in the pathophysiology of coeliac disease. AMG 714 is the first anti-IL-15 monoclonal antibody to be investigated for the treatment of coeliac disease. We aimed to investigate the effects of AMG 714 in patients with coeliac disease who underwent gluten challenge. Methods This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial was done at three clinical sites in Finland. Inclusion criteria included age 18–80 years, a confirmed diagnosis of coeliac disease, and adherence to a gluten-free diet for at least 12 months before screening. Patients were randomly assigned (1:1:1) to 150 mg AMG 714, 300 mg AMG 714, or placebo using permuted blocks and stratified by study site and sex. Patients and study staff were masked to treatment assignment. Treatments were administered by two subcutaneous injections every 2 weeks for 10 weeks (total six doses). Patients without severe villous atrophy at baseline received a gluten challenge (2–4 g daily) during weeks 2–12. Small bowel biopsy samples were obtained for histological assessments at baseline and week 12. The primary efficacy endpoint was the percentage change from baseline to week 12 in villous height-to-crypt depth (VHCD) ratio. Secondary endpoints were CD3-positive intraepithelial lymphocyte density; clinical symptoms measured by gastrointestinal symptom rating scale (GSRS), coeliac disease GSRS, and Bristol stool form scale (BSFS); and changes in anti-tTG and anti-DGP antibodies from baseline. The primary analysis was done in the per-protocol 1 population of patients who received at least one dose of study drug and who underwent the gluten challenge. Safety analyses were done in all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, NCT02637141 and EudraCT, 2015-003647-19. Findings Between April 13, 2016, and Nov 22, 2016, 64 patients were enrolled and randomly assigned to either the 150 mg AMG 714 group (n=22), the 300 mg AMG 714 group (n=22), or the placebo group (n=20). Two patients did not start treatment and two did not provide post-treatment biopsy samples. 49 patients underwent the gluten challenge (per-protocol 1 population) and 11 patients did not because of baseline villous atrophy. AMG 714 did not prevent mucosal injury due to gluten challenge. The least square mean difference in the relative change from baseline in VHCD ratio was −2·49% (95% CI −16·82 to 11·83; p=0·73) between 150 mg AMG 714 and placebo and 6·39% (−7·07 to 19·85; p=0·34) between 300 mg AMG 714 and placebo. Neither comparison was statistically significant. The density of CD3-positive intraepithelial lymphocytes increased in all groups, with smaller increases in the 300 mg group (−41·24% [95% CI −79·28 to −3·20] vs placebo, nominal p=0·03) but not the 150 mg group (−14·32% [–54·39 to 25·74], nominal p=0·47). Clinical symptoms were ameliorated with AMG 714 treatment between baseline and week 12, particularly diarrhoea as measured by the BSFS (nominal p=0·01 for 150 mg vs placebo, and nominal p=0·0002 for 300 mg vs placebo). Serum antibody titres for anti-tTG and anti-DGP antibodies increased in all three treatment groups, with no significant difference between AMG 714 and placebo. Treatment-emergent adverse events occurred in 21 (95%) patients in the 150 mg AMG 714 group, 0 (95%) in the 300 mg AMG 714 group, and 19 (100%) in the placebo group. The most common treatment-emergent adverse events were gastrointestinal disorders (17 [77%] participants in the 150 mg AMG 714 group, 16 [76%] in the 300 mg AMG 714 group, and 13 [68%] in the placebo group). Injection site reactions were the most common individual adverse event, reported in eight (36%) patients in the 150 mg AMG 714 group, 11 (52%) in the 300 mg group, and five (26%) in the placebo group. No serious adverse events occurred. Interpretation The primary endpoint, change in VHCD ratio from baseline after 12 weeks of treatment in patients with coeliac disease undergoing gluten challenge, was not significantly different between placebo and AMG 714 at either 150 mg or 300 mg. Effects on intraepithelial lymphocyte density and symptoms suggest that further research of AMG 714 may be warranted in patients with non-responsive coeliac disease. Funding Celimmune and Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8R60d8应助烟酒不离生采纳,获得10
2秒前
8R60d8应助烟酒不离生采纳,获得10
2秒前
8R60d8应助烟酒不离生采纳,获得10
2秒前
2秒前
量子星尘发布了新的文献求助10
3秒前
橡树果完成签到 ,获得积分10
4秒前
完美小蘑菇应助潇湘雪月采纳,获得10
4秒前
张wx_100完成签到,获得积分10
6秒前
chenjingjing发布了新的文献求助10
6秒前
9秒前
illi发布了新的文献求助10
10秒前
12秒前
13秒前
Ava应助大青山采纳,获得10
14秒前
14秒前
2116564发布了新的文献求助10
16秒前
17秒前
婵婵发布了新的文献求助10
18秒前
ASZXDW发布了新的文献求助20
18秒前
19秒前
Orange应助1235656646采纳,获得10
20秒前
2311发布了新的文献求助10
21秒前
EDSS完成签到,获得积分10
21秒前
勤奋大地完成签到,获得积分10
23秒前
25秒前
2311完成签到,获得积分20
28秒前
共享精神应助小木安华采纳,获得10
30秒前
q1356478314应助2116564采纳,获得10
30秒前
30秒前
刘佳冉完成签到,获得积分10
30秒前
星期八发布了新的文献求助10
31秒前
万能图书馆应助潇湘雪月采纳,获得10
33秒前
黑石完成签到,获得积分10
33秒前
zpc发布了新的文献求助10
34秒前
小郭完成签到,获得积分10
35秒前
37秒前
37秒前
39秒前
文静山兰完成签到 ,获得积分10
39秒前
完美世界应助李嘉欣采纳,获得10
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174